PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Isavuconazonium→

Isavuconazonium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
742049-41-8
Molecular formula
C35H35F2N8O5S+
Molecular weight
717.8 g/mol
Drug class
Isavuconazole prodrugtriazole antifungal
Mechanism of action
Isavuconazonium is hydrolysed to isavuconazole, which inhibits fungal lanosterol 14-alpha-demethylase (CYP51), impairing ergosterol biosynthesis and fungal cell-membrane formation.
Indications / reported uses
  • Treatment of invasive aspergillosis in adults
  • Treatment of invasive mucormycosis in adults; use is product-label specific and should be directed by specialist infectious-disease care

Sources: US DailyMed — CRESEMBA (isavuconazonium sulfate) · EMA EPAR — Cresemba · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Isavuconazonium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Isavuconazonium Permitted Daily Exposure (PDE) report (the Isavuconazonium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Isavuconazonium Occupational Exposure Limit (OEL) report (the Isavuconazonium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.